Article Text

Download PDFPDF

Original research
Association of hyperlipidaemia with 5-year survival after hospitalisation for acute myocardial infarction: a propensity score matched analysis
  1. Mohammed Yousufuddin1,
  2. Ye Zhu2,
  3. Ruaa Al Ward1,
  4. Jessica Peters1,
  5. Taylor Doyle1,
  6. Kelsey L Jensen1,
  7. Zhen Wang3 and
  8. Mohammad Hassan Murad4
  1. 1Internal Medicine, Mayo Clinic Health System, Austin, Minnesota, USA
  2. 2Center for the Science of Health Care Delivery, Mayo Clinic Rochester, Rochester, Minnesota, USA
  3. 3Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota, USA
  4. 4Preventive Medicine and Center for the Science of Health Care Delivery, Mayo Clinic Rochester, Rochester, Minnesota, USA
  1. Correspondence to Dr Mohammed Yousufuddin; yousufuddin.mohammed{at}


Objectives The primary objective was to examine the association between hyperlipidaemia (HLP) and 5-year survival after incident acute myocardial infarction (AMI). The secondary objectives were to assess the effect of HLP on survival to discharge across patient subgroups, and the impact of statin prescription, intensity and long-term statin adherence on 5-year survival.

Methods Retrospective cohort study of 7071 patients hospitalised for AMI at Mayo Clinic from 2001 through 2011. Of these, 2091 patients with HLP (age (mean±SD) 69.7±13.5) were propensity score matched to 2091 patients without HLP (age 70.6±14.2).

Results In matched patients, HLP was associated with higher rate of survival to discharge than no HLP (95% vs 91%; log-rank <0.0001). At year 5, the adjusted HR for all-cause mortality in patients with HLP versus no HLP was 0.66 (95% CI 0.58–0.74), and patients with prescription statin versus no statin was 0.24 (95% CI 0.21 to 0.28). The mean survival was 0.35 year greater in patients with HLP than in those with no HLP (95% CI 0.25 to 0.46). Patients with HLP gained on an average 0.17 life year and those treated with statin 0.67 life year at 5 years after AMI. The benefit of concurrent HLP was consistent across study subgroups.

Conclusions In patients with AMI, concomitant HLP was associated with increased survival and a net gain in life years, independent of survival benefit from statin therapy. The results also reaffirm the role of statin prescription, intensity and adherence in reducing the mortality after incident AMI.

  • hyperlipidaemia
  • mortality
  • acute myocardial infarction
  • statin
  • survival

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

View Full Text

Statistics from


  • Contributors MY, YZ, RAW, JP, TD, RN, KLJ, ZW and MHM contributed substantially to the manuscript and certify that they have NO affiliations with or involvement in any organisation or entity with any financial interest (such as honoraria, educational grants, participation in speakers’ bureaus, membership, employment, consultancies, stock ownership or other equity interest and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Disclaimer Funded by Mayo Clinic Internal Funding, none of the authors have conflict to disclose.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval Study was approved by the Mayo Clinic Institutional Review Board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.